REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Establishment of New Scientific Advisory Board

MaxCyteAnnouncement

08/03/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230308:nRSH3036Sa&default-theme=true

RNS Number : 3036S  MaxCyte, Inc.  08 March 2023

 

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally
Recognized Experts in Cell Engineering Enabling Technology

 

MaxCyte's Scientific Advisory Board will provide guidance to shape the
technical direction of the company's innovation initiatives focused on the
discovery, development and manufacturing of next-generation, cell-based
medicines.

 

ROCKVILLE, MD, March 8, 2023 - MaxCyte, Inc. (https://maxcyte.com/) ,
(Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the formation of its
new Scientific Advisory Board (SAB) that will reflect the cutting edge of
research in molecular design and cell engineering, as well as a deep
understanding of translational development, in order to leverage the benefits
of impactful discoveries for therapeutic applications.

 

"With the formation of our Scientific Advisory Board, we are expanding the
depth and breadth of our leadership team and scientific expertise with the
next generation of leaders in the field of gene and cell therapy," said Doug
Doerfler, President and CEO of MaxCyte. "These four dynamic scientists are
deeply connected in the scientific community through their work and
memberships in professional societies and will bring the innovation and
support needed to nurture our early-stage projects from beginning to end."

 

Each of these individuals has a unique background and brings a diverse
scientific perspective. Supported by deep technical knowledge, the SAB will
help us unlock the power of cells, which will enhance our R&D activities
and portfolio," said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte.
"With the SAB's guidance, we aim to provide our clients with innovative cell
engineering applications that accelerate the development of novel therapies to
improve patient outcomes."

 

 

Members of the MaxCyte Scientific Advisory Board include:

 

Oliver Rando, MD, PhD, is a professor in the Biochemistry and Molecular
Biotechnology Department at the University of Massachusetts Worcester T.H.
Chan School of Medicine and principal investigator within the Rando Lab
(https://www.umassmed.edu/randolab/lab-members/) , which is focused on genomic
approaches to chromatin structure and function, as well as epigenetic
inheritance. He completed his PhD and MD at Stanford University in Palo Alto,
California, working on chromatin remodeling and T-cell activation in the lab
of Jerry Crabtree. Dr. Rando received a Bachelor of Arts in Biochemistry from
Harvard University in Cambridge, Massachusetts while working on the role of
the proteasome in activation of NF-kB in the lab of Tom Maniatis.

 

Marcela Maus, MD, PhD, FABIM, is an associate professor of medicine at Harvard
Medical School and the director of Cellular Immunotherapy at Massachusetts
General Hospital Cancer Center. She oversees the Maus Lab
(https://mauslab.com/maus-lab-team/) , which evaluates next-generation,
genetically modified CAR T-cells as immunotherapy in patients with hematologic
malignancies and solid tumors. Dr. Maus holds graduate degrees (M.D., Ph.D.)
from University of Pennsylvania, where she completed graduate training with
Dr. Carl June. Dr. Maus then trained in internal medicine at University of
Pennsylvania and in hematology and medical oncology at Memorial Sloan
Kettering Cancer Center. She also received a BS in Biology and Literature from
Massachusetts Institute of Technology.

 

Avery Posey, PhD, is an assistant professor in the Department of Systems
Pharmacology and Translational Therapeutics at the University of Pennsylvania
Perelman School of Medicine. The Posey Lab
(https://www.med.upenn.edu/cci/poseylab/) focuses on the development of novel
targets for CAR-T cell therapies, strategies to enhance the functional
persistence of CAR-T cells, and the impact of changes in glycosylation on the
tumor immune microenvironment. Dr. Posey holds a PhD in Genetics from the
University of Chicago, and two BS degrees in Biochemistry and Bioinformatics
from the University of Maryland, Baltimore County (UMBC). He completed his
postdoctoral training in the laboratory of Carl June, where he generated
glycosylation-specific chimeric antigen receptors to precisely target
tumor-glycoforms of MUC1.

 

Nako Nakatsuka, PhD is a senior scientist/principal investigator in the
Laboratory of Biosensors and Bioelectronics at ETH Zurich in Switzerland,
whose research
(https://lbb.ethz.ch/the-group/principal-investigator/nakatsuka-nako.html) is
focused on harnessing artificial DNA-based receptors called aptamers for
small-molecule biosensing. Aptamers are integrated into nanoscale biosensors
to monitor neurotransmitters with the goal of unraveling the basic mechanisms
of neurodegenerative diseases. Beyond neuroscience, novel aptamer-based
biosensors are being developed with the vision of translation for personalized
medicine. Dr. Nakatsuka completed her PhD in Chemistry at the University of
California, Los Angeles, while working in the labs of Anne Andrews and Paul
Weiss. Her thesis exploited aptamers to overcome the conventional bottlenecks
of electronic biosensing of small molecules in complex biological
environments. She also joined the bionanotechnology research lab of Professor
Ipsita Banerjee at Fordham University in New York while completing her BS
degree in Chemistry.

 

 

 

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to support
innovative, cell-based research. Over the past 20 years, we have developed and
commercialized our proprietary Flow Electroporation® technology, which
facilitates complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology, has been
designed to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of next-generation,
cell-based medicines. The ExPERT family of products includes: four
instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary
related processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Seismic Collaborative

Valerie Enes

+1 408-497-8568

valerie@spectrumscience.com (mailto:valerie@teamseismic.com)

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANDPESDDEEA